Premium
Progestin‐based contraceptive on the same day as medical abortion
Author(s) -
Park Jeanna,
Robinson Nuriya,
Wessels Ursula,
Turner James,
Geller Stacie
Publication year - 2016
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2015.08.025
Subject(s) - etonogestrel , medicine , medical abortion , mifepristone , obstetrics , medroxyprogesterone acetate , progestin , misoprostol , gynecology , abortion , contraceptive implant , desogestrel , pregnancy , population , family planning , research methodology , environmental health , biology , genetics , hormone
Objective To determine the success rate of medical abortion when a progestin‐based contraceptive—either an etonogestrel implant or depot medroxyprogesterone acetate (DMPA) injection—is given on the same day as mifepristone for medical abortion. Methods In a retrospective chart review, data were assessed for women aged 15–49 years who underwent medical abortion (≤ 63 days of pregnancy) at two hospitals in KwaZulu Natal, South Africa, between August 2013 and July 2014. The women were given oral mifepristone (200 mg) and buccal misoprostol (800 μg), and received an etonogestrel implant or DMPA injection on the same day as mifepristone. The primary outcome was the success rate of medical abortion. Comparative data were obtained through a PubMed search. Results A total of 89 women were included. Complete termination was achieved in 87 (98%, 95% confidence interval 95%–100%) women. This success rate is similar to that reported in a previous systematic review of the rate of medical abortion success without progestin contraceptive administration (94.8%). Conclusions Administration of a progestin‐based contraceptive such as an etonogestrel implant or DMPA injection on the same day as mifepristone for medical abortion did not alter the success rates.